Your browser doesn't support javascript.
loading
Lung Cancer in Women: The Past, Present, and Future.
Florez, Narjust; Kiel, Lauren; Riano, Ivy; Patel, Shruti; DeCarli, Kathryn; Dhawan, Natasha; Franco, Ivy; Odai-Afotey, Ashley; Meza, Kelly; Swami, Nishwant; Patel, Jyoti; Sequist, Lecia V.
Afiliação
  • Florez N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address: Narjust_florez@dfci.harvard.edu.
  • Kiel L; Dana-Farber Cancer Institute, Boston, MA.
  • Riano I; Section of Hematology and Medical Oncology, Dartmouth Cancer Center, Geisel School of Medicine Dartmouth, Lebanon, NH.
  • Patel S; Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, CA.
  • DeCarli K; Division of Hematology/Oncology, The Warren Alpert Medical School of Brown University, Providence, RI.
  • Dhawan N; Section of Hematology and Medical Oncology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH.
  • Franco I; Department of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Odai-Afotey A; Internal Medicine, Brigham and Women's Hospital, Boston, MA.
  • Meza K; Dana-Farber Cancer Institute, Boston, MA.
  • Swami N; University of Massachusetts Medical School, Worcester, MA; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA.
  • Patel J; Northwestern Medical Group, Chicago, IL.
  • Sequist LV; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
Clin Lung Cancer ; 25(1): 1-8, 2024 01.
Article em En | MEDLINE | ID: mdl-37940410
ABSTRACT
Lung cancer is the leading cause of cancer death for women in multiple countries including the United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences in tolerability and response to therapy in lung cancer, and societal gender roles, that create distinct survivorship needs. Women continue to lack representation in lung cancer clinical trials and are typically treated with data generated from majority male patient study populations, which may be inappropriate to extrapolate and generalize to females. Current lung cancer treatment and screening guidelines do not incorporate sex-specific differences and physicians also often do not account for gender differences when choosing treatments or discussing survivorship needs. To best provide targeted treatment approaches, greater representation of women in lung cancer clinical trials and further research is necessary. Clinicians should understand the unique factors and consequences associated with lung cancer in women; thus, a holistic approach that acknowledges environmental and societal factors is necessary.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pulmonares Limite: Female / Humans / Male País/Região como assunto: America do norte Idioma: En Revista: Clin Lung Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article